Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Go back to Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.11 -0.78 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.89 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $153.23 | P/E | 82.93 | |||
| Day Low | $149.57 | EPS | $1.81 | |||
| Volume | 16,453,710 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 1,800 | |||||
